Clinical trials: Neoadjuvant Treatment
Hepatocellular Carcinoma, Beyond Milan Criteria
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
Surgical resection is the primary curative treatment for patients with hepatocellular carcinoma (HCC), with a 5-year overall survival rate of 60-80% post-surgery.
- Trial name
- NCT06467799
- Testing
- Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer (NSCLC)
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
The purpose of this study is to evaluate the real-world effectiveness and safety of neoadjuvant nivolumab combined with chemotherapy in Argentinian patients with resectable non-small cell lung cancer (NSCLC)
- Trial name
- NCT07141563
- Testing
- Nivolumab + platinum-based chemotherapy
- Where
- Argentina
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved…
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
- Trial name
- NCT06056336
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Guo Xufeng
HIV-1 Infection
4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients
Evaluate after 48 weeks, the capacity of a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment, in HIV-1 treated patients with undetectable viral load for at least 12 months and continuous…
- Trial name
- ANRS162-4D (NCT02157311)
- Testing
- Four consecutive days on treatment and 3 days off
- Where
- 17 sites in France
- Volunteers
- 100 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Melanoma
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma
The purpose of this study is to evaluate the safety and potential effectiveness of a new treatment for advanced and recurrent melanoma involving the combination of Ipilimumab and IFN-α2b before surgery and to test for biomarker…
- Trial name
- NCT01608594
- Testing
- administration of ipilimumab10mg/kg, administration of ipilimumab 3mg/kg + HDI
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Diwakar Davar
Breast Cancer
PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer
The purpose of this study is: To validate the efficacy of multiparametric MRI, FDG-PET, RGD-PET, and PET-MR fusion imaging in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer…
- Trial name
- NCT01190566
- Where
- South Korea
- Volunteers
- 57 people
- Sponsor
- Seoul National University Hospital
Triple Negative Breast Neoplasms
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
This is a single arm open label phase II study in women with clinical stage 2 or 3 triple negative breast cancer to assess the anti-tumor activity (in terms of pathologic complete response rate) of neoadjuvant docetaxel in…
- Trial name
- NCT02124902
- Testing
- Docetaxel, Carboplatin, FDG-PET/MR
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Washington University School of Medicine
Rectal Cancer
Radiation Dose Escalation in Locally Advanced Rectal Cancer
This is a one arm study where patients with locally advanced rectal cancer will receive neoadjuvant treatment with escalated dose radiotherapy (with 3D conformal radiotherapy, up to 59,4 Gy) and radiosensitizing chemotherapy.
- Trial name
- RaDE (NCT02603302)
- Testing
- Dose Escalation Radiotherapy, Delayed surgery
- Where
- Brazil
- Volunteers
- 48 people
- Sponsor
- University of Brasilia
Triple Negative Breast Cancer
A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy
This is a prospective, open-lable phase II clinical trial evaluating the effectiveness and safety of gemcitabine plus cisplatin as adjuvant treatment for non-pCR TNBC patients after standard neoadjuvant chemotherapy.
- Trial name
- nonpCR GP (NCT04297267)
- Testing
- Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Acute Myeloid Leukemia (AML)
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells which perform many functions, including fighting bacterial infections and defending the body against parasites.
- Trial name
- NCT04509622
- Testing
- Venetoclax, Cytarabine
- Where
- 16 sites in Japan
- Volunteers
- 14 people
- Sponsor
- AbbVie
Biphasic Mesothelioma, Epithelioid Mesothelioma
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma.
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7
- Trial name
- NCT03228537
- Testing
- Atezolizumab, Cisplatin, Extrapleural Pneumonectomy
- Where
- 174 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer
This study is being performed so that tumor and blood samples from patients who will receive breast cancer treatment prior to surgery can be collected and stored for future research.
- Trial name
- NCT00161265
- Testing
- tissue procurement
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Michigan Rogel Cancer Center
Liver Transplantation
Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation
An open-label randomized multicenter clinical study comparing three regimes of immunosuppression : (A) tacrolimus and steroids, (B) antithymocyte induction therapy and full dose of tacrolimus, (C) antithymocyte induction therapy…
- Trial name
- BEFIRTH (NCT00538265)
- Testing
- tacrolimus, tacrolimus, ATG, ATG+mycophénolate mofétil+tacrolimus
- Where
- 8 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Toulouse
Breast Cancer
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate
In ER+ and HER2- breast cancer(BC) patients for whom BCS is not feasible, we investigate the rate of BCS can be increased while decreasing unnecessary chemotherapy thru selective neoadjuvant chemotherapy or neoadjuvant endocrine…
- Trial name
- NCT03900637
- Testing
- Leuprorelin acetate, Letrozole, MammaPrint
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- Seoul National University Hospital
Triple-negative Breast Cancer
Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer
The goal of this clinical trial is to learn about the efficacy and safety of short-term sintilimab in combination with taxane and carboplatin for neoadjuvant therapy in female early-stage triple-negative breast caner patients…
- Trial name
- NeoSTEP (NCT05843292)
- Testing
- Taxane and Carboplatin, Short-term Sintilimab, Surgery
- Volunteers
- 48 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Urinary Bladder
A Prospective Study of Neoadjuvant Chemotherapy With Gemcitabine/Platinum in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of Bladder
Previously-untreated, high-risk (>T3 and/or N+) muscle-invasive bladder cancer (MIBC) cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1
- Trial name
- NCT03061630
- Testing
- Gemcitabine, Cisplatin
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Samsung Medical Center
Breast Cancer
Melatonin in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Melatonin is an attractive candidate with anticancer activities previously reported in various preclinical and clinical studies.
- Trial name
- NCT07067307
- Testing
- melatonin
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Mansoura University
Multiple Myeloma
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
This is a randomized, 2-arm phase II, multi-center study to evaluate the overall response rate in newly diagnosed, transplant ineligible patients receiving 9 cycles induction therapy with either KTd or KRd followed by…
- Trial name
- NCT02891811
- Testing
- Carfilzomib, Thalidomide, Lenalidomide
- Where
- 21 sites in Austria, Germany
- Volunteers
- 124 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Colorectal Cancer
A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.
Assuming that the objective response rate (ORR) of neoadjuvant chemotherapy in patients with colorectal cancer peritoneal metastasis is approximately 0.40 , a total sample size of 30 patients is required.
- Trial name
- NCT07268677
- Testing
- pirfenidone plus sintilimab combined with standard neoadjuvant chemotherapy
- Volunteers
- 30 people
- Sponsor
- Guoxiang Cai
Resectable Intrahepatic Cholangiocarcinoma
Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial
This phase II trial tests the safety and effectiveness of preoperative immunotherapy with durvalumab and chemotherapy with cisplatin and gemcitabine with or without futibatinib targeted therapy in treating patients with…
- Trial name
- NCT07639528
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.